ArticleThe journal of prevention of Alzheimer's disease2016
'Alzheimer's Progression Score': Development of a Biomarker Summary Outcome for AD Prevention Trials.
Article in The journal of prevention of Alzheimer's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.Neurology · 2019Trial
- Structural connectome analysis using a graph-based deep model for prediction of non-imaging variables.Frontiers in neuroscience · 2026Article
- Structural Connectome Analysis using a Graph-based Deep Model for Prediction of Non-Imaging Variables.bioRxiv : the preprint server for biology · 2025Article
- Multi-Head Graph Convolutional Network for Structural Connectome Classification.Graphs in biomedical image analysis, and overlapped cell on tissue dataset for histopathology : 5th MICCAI Workshop, GRAIL 2023 and 1st MICCAI Challenge, OCELOT 2023, held in conjunction with MICCAI 2023, Vancouver, BC, Canada, Septembe... · 2024Article
- Article
- Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models.Frontiers in artificial intelligence · 2022Article
- Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.Alzheimer's & dementia (New York, N. Y.) · 2021Review
- Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease.NeuroImage. Clinical · 2021Article
- AD risk score for the early phases of disease based on unsupervised machine learning.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Observational
- APOE4 Status is Related to Differences in Memory-Related Brain Function in Asymptomatic Older Adults with Family History of Alzheimer's Disease: Baseline Analysis of the PREVENT-AD Task Functional MRI Dataset.Journal of Alzheimer's disease : JAD · 2020Observational
- Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline.Journal of Alzheimer's disease : JAD · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlzheimer's disease (AD) prevention research requires methods for measurement of disease progression not yet revealed by symptoms. Preferably, such measurement should encompass multiple disease markers.
objectivesEvaluate an item response theory (IRT) model-based latent variable Alzheimer Progression Score (APS) that uses multi-modal disease markers to estimate pre-clinical disease progression.
designEstimate APS scores in the BIOCARD observational study, and in the parallel PREVENT-AD Cohort and its sister INTREPAD placebo-controlled prevention trial. Use BIOCARD data to evaluate whether baseline and early APS trajectory predict later progression to MCI/dementia. Similarly, use longitudinal PREVENT-AD data to assess test measurement invariance over time. Further, assess portability of the PREVENT-AD IRT model to baseline INTREPAD data, and explore model changes when CSF markers are added or withdrawn.
settingBIOCARD was established in 1995 and participants were followed up to 20 years in Baltimore, USA. The PREVENT-AD and INTREPAD trial cohorts were established between 2011-2015 in Montreal, Canada, using nearly identical entry criteria to enroll high-risk cognitively normal persons aged 60+ then followed for several years.
participants349 cognitively normal, primarily middle-aged participants in BIOCARD, 125 high-risk participants aged 60+ in PREVENT-AD, and 217 similar subjects in INTREPAD. 106 INTREPAD participants donated up to four serial CSF samples. MEASUREMENTS: Global cognitive assessment and multiple structural, functional, and diffusion MRI metrics, sensori-neural tests, and CSF concentrations of tau, Aβ42 and their ratio.
resultsBoth baseline values and early slope of APS scores in BIOCARD predicted later progression to MCI or AD. Presence of CSF variables strongly improved such prediction. A similarly derived APS in PREVENT-AD showed measurement invariance over time and portability to the parallel INTREPAD sample.
conclusionsAn IRT-based APS can summarize multimodal information to provide a longitudinal measure of pre-clinical AD progression, and holds promise as an outcome for AD prevention trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.